French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS. Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis.

• Incident ALS cases identified and followed-up in the participant ALS \& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany.

• Patients who signed the informed consent form.

• Adults aged \>18 years old

Locations
Other Locations
France
CHU de Lille
NOT_YET_RECRUITING
Lille
Limoges University Hospital
RECRUITING
Limoges
Hôpital de la Timone
NOT_YET_RECRUITING
Marseille
Hôpital Gui Chauliac
NOT_YET_RECRUITING
Montpellier
CHU de Nice
NOT_YET_RECRUITING
Nice
Hôpital de la Pitié Salpêtrière
NOT_YET_RECRUITING
Paris
CHU de Tours
NOT_YET_RECRUITING
Tours
Contact Information
Primary
Philippe COURATIER, Pr
philippe.couratier@chu-limoges.fr
05 55 05 15 69
Backup
Andrea ERAZO ALEMAN, Dr
DaniellsAndrea.ERAZOALEMAN@chu-limoges.fr
Time Frame
Start Date: 2024-09-17
Estimated Completion Date: 2029-09-30
Participants
Target number of participants: 1000
Treatments
Other: ALL participants
ALS patients will be stratified in 4 groups according to the weight loss percentage: a) no weight loss; b) \<5% of weight loss; c) 5-10% of weight loss; d) \>10% of weight loss.~In order to identify the genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss.
Sponsors
Collaborators: Centre de Recherche en biomédecine de Strasbourg INSERM UMR-S1118, National Research Agency, France, Klinik für Neurologie, Universitäts- und Rehabilitationskliniken Ulm (RKU), France Cohorte, Institut du Cerveau et de la Moelle épinière, Institut National de la Santé et de la Recherche Médical - délégation Grand Ouest INSERM U1253, Centre de Données Cliniques et de Recherche CDCR, UMR Inserm U1253-IBRain-Neurogénétique et Physiopathologie Neuronale
Leads: University Hospital, Limoges

This content was sourced from clinicaltrials.gov